Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic (Nasdaq: IMUX) appointed veteran biopharmaceutical executive Michael W. Bonney as Chair of the Board of Directors, effective May 16, 2026. Former Interim Chairperson Simona Skerjanec remains on the board.
Bonney brings 30+ years of leadership, including key roles in the launch of Avonex for multiple sclerosis at Biogen and a decade as CEO of Cubist Pharmaceuticals, which was acquired by Merck for approximately $9.5 billion. He also chairs several other biotech boards.
The appointment comes as Immunic advances its oral MS candidate vidofludimus calcium, including phase 3 ENSURE trials in relapsing MS and a planned phase 3 program in primary progressive MS, supporting the company’s plans to evolve into a commercial-stage organization.
Immunic (Nasdaq: IMUX) reported Q1 2026 results and a corporate update. The company is running phase 3 ENSURE trials of vidofludimus calcium in relapsing MS, with top-line data expected by end 2026 and a planned U.S. NDA in mid-2027.
Immunic closed an oversubscribed private placement of up to $400 million, receiving $200 million upfront, and ended March 31, 2026 with $186.6 million in cash, expected to fund operations into late 2027. Q1 2026 net loss was $32.6 million on higher R&D and G&A expenses. The company appointed Michael A. Panzara as CMO, implemented a 1-for-10 reverse stock split, regained Nasdaq minimum bid compliance, and obtained a key European patent for vidofludimus calcium dosing regimens, expected to provide protection into 2038.
Immunic (Nasdaq: IMUX) will attend investor and medical conferences in May 2026, including Bio€quity Europe (May 4-6, 12-13) and the CMSC Annual Meeting (May 27-29).
Management will hold one-on-ones at Bio€quity; Immunic will present one late-breaking poster and two posters at CMSC on May 28 and staff the booth #307.
Immunic (Nasdaq: IMUX) appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer effective April 24, 2026. Dr. Panzara will lead clinical development, medical affairs, and regulatory affairs and succeeds Andreas Muehler, who will serve as a consultant.
Dr. Panzara brings 25+ years in neurology, led global regulatory approvals for LEMTRADA and AUBAGIO, was global clinical lead for TYSABRI, and will guide vidofludimus calcium through the phase 3 ENSURE readout and planned primary progressive MS trial. The board granted a 300,000-share option inducement with time-based vesting.
Immunic (Nasdaq: IMUX) will effect a 1-for-10 reverse stock split at 12:01 a.m. ET on April 27, 2026, reducing outstanding shares from approximately 136 million to 13.6 million. The split is intended to help meet contractual obligations under a February 12, 2026 securities purchase agreement.
No fractional shares will be issued; fractional interests will be aggregated, sold, and cash paid to holders. The split does not change authorized shares, par value, or ownership percentages except for cash-in-lieu for fractions. Outstanding equity awards will be proportionally adjusted.
Immunic (Nasdaq: IMUX) will participate in scientific and medical conferences in April 2026, presenting preclinical and clinical science on its lead asset vidofludimus calcium (IMU-838).
April 14-16: 8th Annual Neuroimmunology Drug Development Summit in Boston; Dr. Hella Kohlhof will present on April 16 at 12:00 pm ET. April 18-22: American Academy of Neurology Annual Meeting in Chicago; Immunic team available at booth #3830. Presentation will be posted in the company's Events and Presentations web section.
Immunic (Nasdaq: IMUX) notified investors that it has regained compliance with Nasdaq's minimum bid price rule.
According to the company, the closing bid price remained at or above $1.00 per share for at least 20 consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2) on March 26, 2026, and the Listing Qualifications matter was closed.
Immunic (Nasdaq: IMUX) announced on March 31, 2026 the appointment of Jon Congleton to its Board of Directors, effective March 27, 2026.
Mr. Congleton brings nearly 40 years of biopharmaceutical experience, including leadership in CNS commercialization and a role in the U.S. launch of Copaxone. He currently serves as CEO of Mineralys and will support advancement of vidofludimus calcium toward pivotal trial readouts later in 2026 and the company’s transition to a commercial-stage firm.
Immunic (Nasdaq: IMUX) announced that the European Patent Office granted patent EP3713554 covering label-relevant dosing regimens for vidofludimus calcium, protecting all forms (salts, solvates, free acid) in Europe into 2038. The patent may be eligible for an SPC to extend exclusivity potentially into 2043. The USPTO previously granted related protection in 2023; existing U.S. patents provide protection into 2041, and pending filings could extend certain rights into the mid-2040s.
Immunic (Nasdaq: IMUX) will attend investor conferences in March 2026, presenting leadership panels and offering one-on-one investor meetings.
Executives Daniel Vitt, Ph.D., Jason Tardio and Jessica Breu will appear at the Leerink Partners Global Healthcare Conference (March 8–11) and the Stifel 2026 Virtual CNS Forum (March 17–18). Webcasts will be available on the company's Events and Presentations page.